Results 71 to 80 of about 77,108 (288)

Elemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis

Advanced Science, EarlyView.
Elemene increases SPP expression by competitively binding with miR‐130a‐5p to suppress SPP mRNA degradation. This led to more antigen/MHC‐I complexes being expressed on the cell surface, which consequently facilitated the recognition and killing of HCC cells by CTLs and enhancing the antitumor immune efficacy of anti‐PD‐1.
Menglan Wang, Mengqing Sun, Heng Dong, Xiaoting Zhang, Jingbo Zhang, Zhengguo Zhang, Mengjie Ni, Lina Li, Yunxin Pei, Xiaoyu Chen, Qian Li, Fangtian Bu, Jiacheng Huang, Liangyu Jiang, Zhuting Fang, Xuliang Chen, Jianxiang Chen, Yiting Qiao, Tian Xie   +18 more
wiley   +1 more source

Ipilimumab-Induced Neutropenia in Melanoma

Journal of Investigative Medicine High Impact Case Reports, 2016
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related.
Makiko Ban-Hoefen MD, Richard Burack MD, Lynn Sievert NP, Deepak Sahasrabudhe MD   +3 more
doaj   +1 more source

Nivolumab plus ipilimumab in the treatment of advanced melanoma. [PDF]

, 2015
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that
Daud, Adil I, Tsai, Katy K
core   +1 more source

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. [PDF]

, 2018
BackgroundMucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), -002 (NCT01704287), and -006 (NCT01866319).MethodsPatients received ...
Arance, Ana S, Brown, Ewan, Butler, Marcus, Daud, Adil, Ebbinghaus, Scot, Hamid, Omid, Hodi, F Stephen, Hoeller, Christoph, Ibrahim, Nageatte, Long, Jianmin, Mortier, Laurent, Ribas, Antoni, Robert, Caroline, Schachter, Jacob, Walpole, Euan   +14 more
core   +1 more source

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Nature Communications, 2021
Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non-randomized phase Ib/IIa trial, 32 HNSCC patients are treated with 2 doses (in weeks 1 and 3 ...
J. Vos, J. Elbers, O. Krijgsman, J. Traets, X. Qiao, A. M. van der Leun, Yoni Lubeck, I. M. Seignette, L. Smit, S. Willems, M. van den Brekel, R. Dirven, M. Baris Karakullukcu, Luc H E Karssemakers, W. Klop, P. Lohuis, W. H. Schreuder, L. Smeele, L. van der Velden, I. Bing Tan, Suzanne Onderwater, B. Jasperse, W. Vogel, A. Al-Mamgani, A. Keijser, V. van der Noort, A. Broeks, E. Hooijberg, D. Peeper, T. Schumacher, C. Blank, J. D. de Boer, J. Haanen, C. Zuur   +33 more
semanticscholar   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. [PDF]

PLoS ONE, 2018
Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized that CTLA-4 blockade may enhance immune response to HIV-1 and result in better control of ...
Elizabeth Colston, Dennis Grasela, David Gardiner, R Pat Bucy, Blisse Vakkalagadda, Alan J Korman, Israel Lowy   +6 more
doaj   +1 more source

Full Issue: Volume 13, Issue 1 - Winter 2018 [PDF]

, 2018
Full Issue: Volume 13, Issue 1 - Winter ...

core   +1 more source

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis [PDF]

, 2009
Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities.
Clatworthy, Menna R, Farrington, Ken, Jolly, Elaine C, Lawrence, Christopher, Nathan, Paul D   +4 more
core   +2 more sources

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Journal of Clinical Oncology, 2022
PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV ...
J. Weber, D. Schadendorf, M. Del Vecchio, J. Larkin, V. Atkinson, M. Schenker, J. Pigozzo, H. Gogas, S. Dalle, N. Meyer, P. Ascierto, S. Sandhu, T. Eigentler, R. Gutzmer, J. Hassel, C. Robert, M. Carlino, A. D. Di Giacomo, M. Butler, E. Muñoz-Couselo, Michael P. Brown, P. Rutkowski, A. Haydon, J. Grob, J. Schachter, P. Queirolo, L. de la Cruz-Merino, A. van der Westhuizen, A. Menzies, S. Re, T. Bas, V. de Pril, J. Braverman, D. Tenney, Hao Tang, G. Long   +35 more
semanticscholar   +1 more source